Caszyme, a leading company in the development and application of CRISPR technology, announces that Chief Executive Officer and Co-Founder, Dr. Monika Paulė, has chosen to step down from the CEO position at the company to pursue other interests.
Dr. Monika Paulė co-founded Caszyme in 2017 with Prof. Virginijus Šikšnys and Dr. Giedrius Gasiūnas. As CEO of the company, she oversaw a rapidly growing portfolio of projects, securing major collaborations and establishing a global reputation for Caszyme’s CRISPR technology in the healthcare, therapeutics, diagnostics, agritech, research tools, foodtech and aquaculture sectors.
Dr. Giedrius Gasiūnas, fellow Co-Founder and currently CSO will assume the role of Interim CEO. A search for Dr. Paulė’s replacement on Caszyme’s leadership team is underway. Dr. Monika Paulė will retain her Caszyme Board position.
“The last decade has seen gene editing realising its potential and Caszyme has been an important part of it,” said Dr. Monika Paulė. “Having led the company from inception to its current established position, I now feel the time is right to step down. I would like, first of all, to thank each and every Caszyme team member for the incredible work done. I would also like to thank my fellow Co-Founders and Board members for their support during what has been a challenging yet exciting and rewarding last 10 years. ”
Caszyme Chair Prof. Virginijus Šikšnys added: “I would like to thank Monika both personally and on behalf of the Caszyme Board for her outstanding work in helping Caszyme come so far in such a relatively short time. I wish her success in whatever she does next.”
About Caszyme
Caszyme is a gene editing company which combines its deep experience and dynamic platform to deliver world class CRISPR solutions. Caszyme was established in 2017 by Dr. Monika Paule, Dr. Giedrius Gasiunas and Prof. Virginijus Šikšnys – a pioneer of CRISPR-Cas gene editing research. Over the last 8 years, Caszyme has rapidly advanced its excellence and capabilities as an enabling expert partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities. Company has a long-term expertise in discovery and development of novel gene editing tools, proteins evolution and engineering, mRNA synthesis and optimization. Also Caszyme has developed a platform of unique CRISPR nucleases. This enables Caszyme partners across various industries effectively apply CRISPR gene editing technology and tools for their market-ready products. Currently, in the therapeutics field Caszyme aims to develop safer and more compact gene editing tools for treating genetic eye diseases in vivo as well as develops a CRISPR based diagnostics platform.